Helps companies understand data integration needs from business, technology perspectives

DAYTON, Ohio, Feb. 7, 2011 /PRNewswire/ -- Teradata Corporation (NYSE: TDC), the world's largest company solely focused on data warehousing and enterprise analytics, today announced the general availability of its Life Sciences Logical Data Model (LS-LDM). The latest of Teradata's industry LDMs will benefit life sciences (including pharmaceutical) companies as they integrate, centralize and analyze data used across the business. The LDM accelerates answers to questions about the business, ranging from sales, marketing and financial to clinical research and supply chain data.

(Logo: http://photos.prnewswire.com/prnh/20090909/TERADATALOGO )

An LDM serves as a blueprint for building an enterprise data structure that provides common business definitions for all entities, resulting in a single, integrated view across the life sciences organization.  It also documents business rules at the corporate level, supports consistent reporting and analytical results, and helps eliminate data redundancy.  

"With increasing momentum, the life sciences industry is turning to Teradata for data warehousing solutions to integrate, organize and analyze highly granular data for deep visibility and decision support pertaining to every aspect of the business and its products," said John Burke, vice president of industry marketing and solutions. "By introducing the LS-LDM, Teradata is responding to the growing demand for data warehousing as well as reinforcing our commitment in the life sciences industry."

"This is a smart step forward for Teradata and good news for large and growing pharmaceutical companies interested in a comprehensive, enterprise-wide data model," said Dr. Jeffrey L. Moe, Executive in Residence, Duke University.

Teradata has invested in the creation of an extensive industry model that covers the broad spectrum on life sciences from clinical subject areas to financial and human resources, to manufacturing, and sales and marketing. The LS-LDM was developed to closely align with CDISC and HL7 industry standards. The clinical extension of the LS-LDM is a BRIDG-based logical data model designed to increase clinical trial ROI by improving clinical trial decision-making through improved data quality based on the capacity to deliver precise answers to complex clinical questions in near real time.

Burke said that the clinical extension of the LS-LDM addresses the life sciences industry's top of mind business problems, including the number one issue: how to improve the ROI on clinical trials.  "The primary reason for this problem is the escalating cost to bring a drug to market," Burke said. "The latest statistic published in PhRMA's 2010 Industry Profile, reveals that it costs $1.3 billion to bring a new chemical entity to market and $1.2 billion to bring a biologic agent to market. Teradata's LS-LDM addresses the need to define data standards that will enable new business models, deliver higher-return drug portfolios, enable data sharing and accelerate the new drug application (NDA) process."

Teradata's momentum in the Life Sciences industry is characterized by the adoption of Teradata-driven analytic platforms at leading life sciences and pharmaceutical companies.

About Teradata

Teradata Corporation (NYSE: TDC) is the world's largest company solely focused on raising intelligence and achieving enterprise agility through its database software, enterprise data warehousing, data warehouse appliances, consulting, and enterprise analytics.   Visit Teradata on the web at www.teradata.com.

Teradata is a trademark or registered trademark of Teradata Corporation in the United States and other countries.

SOURCE Teradata Corporation

Back to top

RELATED LINKS
http://www.teradata.com